Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) shares traded down 2.2% on Thursday . The stock traded as low as $0.13 and last traded at $0.14. 8,794,663 shares were traded during trading, a decline of 48% from the average session volume of 16,965,762 shares. The stock had previously closed at $0.14.
Analysts Set New Price Targets
Separately, Noble Financial upgraded shares of Zomedica to a "strong-buy" rating in a research note on Monday, November 11th.
View Our Latest Report on ZOM
Zomedica Stock Performance
The firm has a market capitalization of $128.37 million, a PE ratio of -2.18 and a beta of 1.04.
Institutional Investors Weigh In On Zomedica
A hedge fund recently raised its stake in Zomedica stock. Geode Capital Management LLC lifted its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 3.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,929,716 shares of the company's stock after purchasing an additional 321,395 shares during the period. Geode Capital Management LLC owned 1.01% of Zomedica worth $1,363,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.95% of the company's stock.
About Zomedica
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
